Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
213.20
+1.31 (+0.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
39
40
Next >
7 Undervalued S&P 500 Stocks to Buy in June
June 15, 2023
If you want to maximize your upside potential in a relatively predictable arena, these undervalued S&P 500 stocks could be for you.
Via
InvestorPlace
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed
June 14, 2023
Senator Bernie Sanders vowed to oppose President Joe Biden's nominated candidate, Monica Bertagnolli, or any other current or future health agency nominee, to lead the National Institutes of Health...
Via
Benzinga
Why Biogen Stock Is Trading Down Today
June 13, 2023
Biogen Inc. (NASDAQ: BIIB) shares fell Tuesday after it was deemed that the ability of the company's Alzheimer's drug, Leqembi, to slow cognitive decline may not outweigh its risks, according to...
Via
Benzinga
Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday
June 13, 2023
U.S. stocks traded higher, with the Dow Jones rising around 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories
June 13, 2023
Benzinga
Via
Benzinga
Expert Ratings for Biogen
June 08, 2023
Via
Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
June 13, 2023
Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow
Via
Benzinga
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground
June 12, 2023
For the bull run to continue we need broader market participation from SMID caps.
Via
Talk Markets
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
June 12, 2023
Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) Phase 3 Clarity AD tria
Via
Benzinga
Why Are Cruise Stocks CCL, RCL, NCLH Up Today?
June 12, 2023
Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details!
Via
InvestorPlace
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing
June 12, 2023
Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday.
Via
InvestorPlace
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
June 05, 2023
Via
Benzinga
Biogen Unusual Options Activity For May 26
May 26, 2023
Via
Benzinga
Analyst Ratings for Biogen
May 23, 2023
Via
Benzinga
Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
June 12, 2023
Via
Benzinga
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
June 09, 2023
A panel of experts will debate the merits of Biogen's drug, Leqembi.
Via
Investor's Business Daily
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
June 08, 2023
Senator Bernie Sanders urged the U.S.
Via
Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
June 08, 2023
FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for...
Via
Benzinga
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
June 07, 2023
The FDA's advisors will consider the full approval of Leqembi on Friday.
Via
Investor's Business Daily
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today
May 19, 2023
Via
Benzinga
Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio
June 07, 2023
When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several...
Via
Benzinga
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
June 05, 2023
Via
Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
June 02, 2023
Big Pharma is facing a patent cliff that could siphon off billions in revenue.
Via
Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
June 01, 2023
The news also benefits Biogen's partner Eisai and rival Eli Lilly.
Via
Investor's Business Daily
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
June 01, 2023
Shares surged into and out of the company's R&D Day, which included a surprise.
Via
Investor's Business Daily
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
May 30, 2023
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers.
Via
Talk Markets
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
May 19, 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher.
Via
InvestorPlace
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
May 19, 2023
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
Via
The Motley Fool
Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.
May 15, 2023
An analyst says Lilly's donanemab could become a blockbuster in its second year on the market.
Via
Investor's Business Daily
These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win
May 14, 2023
There's no rule that says a market must have only one winner.
Via
The Motley Fool
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.